Economy

Novartis to acquire cancer drug specialist Advanced Accelerator Applications

Novartis to acquire cancer drug specialist Advanced Accelerator Applications”

Novartis has unveiled plans to buy Advanced Accelerator Applications (AAA) for $3.9 billion in cash, beefing up its oncology portfolio.

In September, Advanced Accelerator won European Union approval of a radioligand therapy called Lutathera for use as a treatment of neuroendocrine tumors. Lutathera is under review in the USA with a Prescription Drug User Fee Act (PDUFA) date of January 26, 2018.

Per deal terms, Novartis will pay $41 per ordinary share of Advanced Accelerator and $82 per American Depositary Shares - representing a 47% premium to the 30 volume-weighted trading days prior to a September 27 Bloomberg report that flagged Novartis as a potential suitor for the French company.

In announcing the deal, Novartis touted Advanced Accelerator's capabilities in developing and manufacturing radiopharmaceuticals, which contain radioisotopes to destroy unhealthy cells or diagnose cancers. This transaction is now valued up to $3.9 billion.

The acquisition will strengthen Novartis' oncology presence with near-term product launches and the addition of a new technology platform with potential applications across a number of oncology fields.

Improve the format, traceability, uniformity, and completeness relating to clinical data-including from the Phase III NETTER-1 trial, which generated positive results.

Bruno Strigini, chief executive officer of Novartis Oncology, said: "Novartis has a strong legacy in the development and commercialisation of medicines for neuroendocrine tumours where significant unmet need remains for patients".

The study met its primary endpoint with Lutathera achieving statistically significant and clinically meaningful 79% reduction in risk of disease progression or death compared to the control therapy (hazard ratio 0.21, 95% confidence interval: 0.13-0.33, p 0.0001).

Advanced Accelerator Application develops molecular nuclear medicine, including Lutathera. AAA had sales of €109 million in 2016.

The acquisition is subject to the approval of regulators and at least 80% of the shares in question have to be tendered for the deal to go through.



Like this

Latest


30 October 2017
White House decorated for Halloween
The web of decorations were put up on Friday ahead of the First Lady's Halloween event for trick-or-treaters. President Trump invited the children of White House reporters into the Oval Office over the weekend.

30 October 2017
Pixelgate: Pixel 2 owners reporting Android Auto UI randomly crashing
As the accounts being related increased in volume, along with complaints, Google announced that it would investigate the issue. The device records voice clearly, but background sounds like running water result in a high-pitched screeching sound.

30 October 2017
Eagle Global Advisors LLC Has $30.27 Million Position in Apple Inc. (AAPL)
Advisor Prtnrs Limited Liability Corporation owns 3.88% invested in Apple Inc. 403,889 were accumulated by Northern Trust Corp. Pure Fincl holds 0.67% of its portfolio in Apple Inc. (NASDAQ:AAPL) or 10,000 shares. (NASDAQ:AAPL) for 192,531 shares.

30 October 2017
IDF destroys tunnel extending from central Gaza into Israel
The agency, UNRWA, condemned the apparent violation of its sovereignty but did not specify who might have dug the tunnel. The school was immediately closed and the tunnel sealed, according to the statement.

30 October 2017
Champion jockey loses Melbourne Cup ride
Oliver did not comment on whether he would appeal the ban which will keep him out from after Sunday's meeting until November 16. Frankie Dettori has been booked to ride last year's victor Almandin as the jockey seeks a first Melbourne Cup win.

30 October 2017
NBC, MSNBC Part Ways With Mark Halperin After Sexual Harassment Allegations
For that, I am deeply sorry and I apologize. "I know I can never do enough to make up for the harm I caused", he said. Both networks immediately suspended Halperin after the allegations became public last week.

30 October 2017
Qualcomm Could Announce Snapdragon 845 Processor In December
The new chipset is also optimised for augmented reality (AR) and virtual (VR) that are making their way to lot of smartphones. Moreover, Gizmochina reports that Xiaomi is in works with Qualcomm to optimise its chipset Snapdragon 845 v2 for Mi 7.

30 October 2017
Guardiola wants more from 'special' Sane
But Guardiola says Sane, 21, and Sterling, 22, must not stop trying to develop their games if they are to get to the very top. We had a recovery day, yesterday we were off.

30 October 2017
Samsung Galaxy S9 and S9+ rumors suggest big changes to design
The release date is not yet decided of the phone but it is expected that the phone will be revealed by end of 2017. The phone is foldable and will surely have good features, therefore, it will be expensive.

30 October 2017
Price Target Analysis Amazon.com, Inc
Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Amazon.com by 125.1% during the second quarter. Palisades Hudson Asset Management LP owns 998 shares or 0.57% of their United States portfolio. (NASDAQ: AMZN ).